A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of
PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts
response to PM01183 in Metastatic Breast Cancer (MBC) patients, to evaluate the safety
profile of this PM01183 to analyze the pharmacokinetics (PK) and PK/PD
(pharmacokinetic/pharmacodynamic) correlations and to evaluate the pharmacogenomic (PGx)
expression profile in tumor samples.